The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A randomized phase II study of anti-PD1 antibody [MK-3475 (Pembrolizumab)] alone versus anti-PD1 antibody plus stereotactic body radiation therapy in advanced merkel cell carcinoma (Alliance A091605).
 
Jason J. Luke
Honoraria - Intellisphere, LLC
Consulting or Advisory Role - 7 Hills Pharma; Actym Therapeutics; Amgen; Array BioPharma; AstraZeneca/MedImmune; Benevir; Bristol-Myers Squibb; Castle Biosciences; Checkmate Pharmaceuticals; EMD Serono; Gilead Sciences; Janssen; Merck; Newlink Genetics; Novartis; Reflexion Medical; Syndax; Tempest Therapeutics
Research Funding - Abbvie; Boston Biomedical; Bristol-Myers Squibb; Celldex; Checkmate Pharmaceuticals; Corvus Pharmaceuticals; Delcath Systems; Five Prime Therapeutics; Genentech/Roche; Immunocore; Incyte; Macrogenics; MedImmune; Merck; Novartis; Palleon Pharmaceuticals; Pharmacyclics; Tesaro
Travel, Accommodations, Expenses - Amgen; Array BioPharma; AstraZeneca/MedImmune; Benevir; Bristol-Myers Squibb; Castle Biosciences; Checkmate Pharmaceuticals; EMD Serono; Gilead Sciences; Janssen; Merck; Novartis; Reflexion Medical
 
Steven J. Chmura
No Relationships to Disclose
 
Jacob B Allred
No Relationships to Disclose
 
Joseph Kamel Salama
Honoraria - Reflexion Medical
Consulting or Advisory Role - Bristol-Myers Squibb (I); Merck (I)
Speakers' Bureau - Bristol-Myers Squibb (I)
Research Funding - AbbVie; Bristol-Myers Squibb (I); Celldex (I); Dynavax Technologies (I); Genentech/Roche (I); Immunocore (I); Merck (I); Reata Pharmaceuticals (I)
 
Hania A Al-Hallaq
No Relationships to Disclose
 
Charles Hsu
No Relationships to Disclose
 
Sue S. Yom
No Relationships to Disclose
 
Mark Kozloff
Honoraria - Abbvie; Genentech/Roche
Consulting or Advisory Role - Abbvie; Genentech/Roche
Speakers' Bureau - Abbvie; Amgen; Genentech/Roche; Lilly; Merck; Tesaro
 
Pamela N. Munster
Stock and Other Ownership Interests - OncoSec (I)
Honoraria - Amgen (I); Prometheus (I); Threshold Pharmaceuticals
Consulting or Advisory Role - HUYA Bioscience International
Research Funding - Andes Biotechnologies (Inst); Biomarin (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Immune Design (Inst); Intellikine (Inst); Merck (Inst); Merrimack (Inst); Nektar (Inst); Novartis (Inst); OncoMed (Inst); Onconova Therapeutics (Inst); oncosec (Inst); Pfizer (Inst); Piramal Life Science (Inst); Plexxikon (Inst); Sanofi (Inst)
 
Gary K. Schwartz
Honoraria - BioMotiv; Bionaut Labs; Champions Oncology; Daiichi Sankyo; DarwinHealth; Human Longevity, Inc; Karyopharm Therapeutics
Consulting or Advisory Role - BioMotiv; Bionaut Labs; Champions Oncology; Daiichi Sankyo; DarwinHealth; Human Longevity, Inc; Karyopharm Therapeutics; PureTech
Research Funding - Astex Pharmaceuticals
Patents, Royalties, Other Intellectual Property - Patent pending regarding development of PNAs for targeted cancer therapy (new technology)
Travel, Accommodations, Expenses - Daiichi Sankyo